Jerusalem Pharmaceuticals Valuation

Is JPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JPH ($3.58) is trading above our estimate of fair value ($0.59)

Significantly Below Fair Value: JPH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JPH?

Key metric: As JPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JPH. This is calculated by dividing JPH's market cap by their current earnings.
What is JPH's PE Ratio?
PE Ratio	15.7x
Earnings	US$4.11m
Market Cap	US$64.44m

JPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	7.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does JPH's PE Ratio compare to its peers?

The above table shows the PE ratio for JPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	19.5x
BPC Birzeit Pharmaceuticals	39.2x	n/a	US$140.3m
PHARMACARE Dar Al-Shifa Pharmaceuticals	6.2x	n/a	US$30.2m
BJP Beit Jala Pharmaceutical	15.3x	n/a	د.أ19.6m
OPC OPC Pharmaceutical	17.4x	n/a	₫1.5t
JPH Jerusalem Pharmaceuticals	15.7x	n/a	US$64.4m

Price-To-Earnings vs Peers: JPH is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (23.9x).

Price to Earnings Ratio vs Industry

How does JPH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

11 Companies	Price / Earnings	Estimated Growth	Market Cap

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: JPH is good value based on its Price-To-Earnings Ratio (15.7x) compared to the Asian Pharmaceuticals industry average (24.2x).

Price to Earnings Ratio vs Fair Ratio

What is JPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JPH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.